Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression

被引:35
|
作者
Peters, Lars [1 ]
Mocroft, Anianda [2 ]
Soriano, Vincent [3 ]
Rockstroh, Juergen K. [4 ]
Losso, Marcelo [5 ]
Valerio, Laure [6 ]
Aldins, Pauls [7 ]
Reiss, Peter [8 ]
Ledergerber, Bruno [9 ]
Lundgren, Jens D. [10 ,11 ]
机构
[1] Univ Copenhagen, Fac Hlth Sci, Copenhagen HIV Programme, Panum Inst, DK-2200 Copenhagen N, Denmark
[2] UCL, Sch Med, Res Dept Infect & Populat Hlth, London W1N 8AA, England
[3] Hosp Carlos III, Madrid, Spain
[4] Univ Bonn, Dept Internal Med, D-5300 Bonn, Germany
[5] Hosp JM Ramos Mejia, Buenos Aires, DF, Argentina
[6] CHU Nice, Hop Archet 1, Nice, France
[7] Infectol Ctr Latvia, Riga, Latvia
[8] Univ Amsterdam, Acad Med Bij, Amsterdam, Netherlands
[9] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[10] Rigshosp, Div Infect Dis, Ctr Viral Dis KMA, DK-2100 Copenhagen, Denmark
[11] Rigshosp, Hosp Epidemiol, Ctr Viral Dis KMA, DK-2100 Copenhagen, Denmark
关键词
antiretroviral therapy; CD4; hepatitis; HIV; viral load; HIV-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; FIBROSIS PROGRESSION; INDIVIDUALS; DISEASE; IMPACT;
D O I
10.1097/QAI.0b013e318198a0e1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Conflicting data exist whether hepatitis C virus (HCV) affects the CD4 cell recovery in patients with HIV starting antiretroviral treatment. Objective: To investigate the influence of HCV coinfection on the CD4 recovery in patients with maximum virologic suppression within the EuroSIDA cohort. Methods: Patients tested for anti-HCV antibodies and with at least 2 consecutive HIV viral loads (VLs) <50 copies per milliliter after starting combination antiretroviral therapy were eligible for inclusion. For each pair of VL <50 copies per milliliter, the annual change in CD4 count was calculated and compared between (1) HCV-seronegative vs. HCV-seropositive patients, (2) HCV genotypes 1-4 in HCV-RNA+ patients, and (3) viremic vs. aviremic (HCV-RNA < 615 IU/mL) in HCV-seropositive patients. Results were adjusted for known confounders. Results: Four thousand two hundred eight patients were included, representing 39,474 pairs of HIV VL measurements with VL <50 copies per milliliter and 12,492 person-years of follow-tip. The unadjusted annual change in CD4 count for HCV-seropositive and HCV-seronegative patients was 35.5 cells per milliliter (95% confidence interval 27.2 to 43.9) and 38.3 cells per milliliter (95% confidence interval 34.8 to 41.9), respectively. After adjustment, there was no difference in CD4 change when comparing, according to HCV serostatus (P = 0.17), between genotypes (P = 0.23) or when comparing HCV viremic vs. aviremic patients (P = 0.57). Adjusting additionally for HCV treatment and HCV-RNA VL did not change the findings. Conclusions: HCV serostatus did not influence the CD4 recovery in patients with HIV with maximum virologic suppression after starting combination antiretroviral therapy. Furthermore, no difference in CD4 gain was found when comparing distinct HCV genotypes in HCV-RNA+ patients or when comparing HCV viremic vs. aviremic HCV-seropositive patients.
引用
收藏
页码:457 / 463
页数:7
相关论文
共 50 条
  • [1] Influence of hepatitis C virus coinfection on CD4+ T cells of HIV-infected patients receiving HAART
    Shmagel, Konstantin V.
    Saidakova, Evgeniya V.
    Korolevskaya, Larisa B.
    Shmagel, Nadezhda G.
    Chereshnev, Valeriy A.
    Anthony, Donald D.
    Lederman, Michael M.
    AIDS, 2014, 28 (16) : 2381 - 2388
  • [2] CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART
    Sauter, Rafael
    Huang, Ruizhu
    Ledergerber, Bruno
    Battegay, Manuel
    Bernasconi, Enos
    Cavassini, Matthias
    Furrer, Hansjakob
    Hoffmann, Matthias
    Rougemont, Mathieu
    Gunthard, Huldrych F.
    Held, Leonhard
    MEDICINE, 2016, 95 (42)
  • [3] Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection
    Nicolas, David
    Esteve, Anna
    Cuadros, Anna
    Campbell, Colin N. J.
    Tural, Cristina
    Podzamczer, Daniel
    Murillas, Javier
    Homar, Francesc
    Segura, Ferran
    Force, Lluis
    Vilaro, Josep
    Masabeu, Angels
    Garcia, Isabel
    Mercadal, Jordi
    Montoliu, Alexandra
    Ferrer, Elena
    Riera, Melcior
    Cifuentes, Carmen
    Ambrosioni, Juan
    Navarro, Gemma
    Manzardo, Christian
    Clotet, Bonaventura
    Gatell, Josep M.
    Casabona, Jordi
    Miro, Jose M.
    CLINICAL INFECTIOUS DISEASES, 2016, 62 (12) : 1578 - 1585
  • [4] T-Cell Dysfunction in HIV-1-Infected Patients With Impaired Recovery of CD4 Cells Despite Suppression of Viral Replication
    Erikstrup, Christian
    Kronborg, Gitte
    Lohse, Nicolai
    Rye, Ostrowski Sisse
    Gerstoft, Jan
    Ullum, Henrik
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 53 (03) : 303 - 310
  • [5] Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection
    Weimer, Liliana Elena
    Fragola, Vincenzo
    Floridia, Marco
    Guaraldi, Giovanni
    Ladisa, Nicoletta
    Francisci, Daniela
    Bellagamba, Rita
    Degli Antoni, Anna
    Parruti, Giustino
    Giacometti, Andrea
    Manconi, Paolo Emilio
    Vivarelli, Angela
    D'Ettorre, Gabriella
    Mura, Maria Stella
    Cicalini, Stefania
    Preziosi, Roberta
    Sighinolfi, Laura
    Verucchi, Gabriella
    Libertone, Raffaella
    Tavio, Marcello
    Sarmati, Loredana
    Bucciardini, Raffaella
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (01) : 193 - 199
  • [6] CD4+T-cell recovery in HIV/hepatitis C co-infected patients following successful hepatitis C treatment
    Ryscavage, Patrick
    Hussien, Siham
    Seung, Hyunuk
    Hynicka, Lauren
    HIV MEDICINE, 2024, 25 (05) : 622 - 627
  • [7] Evaluation of Right Ventricular Diastolic Function among HIV-1-Infected Patients on Highly Active Antiretroviral Therapy and its Relationship with CD4 Cell Count and Viral Load
    Baba, Musa Mohammed
    Ayoola, Yekeen Ayodele
    Abdul, Habu
    Buba, Faruk
    Talle, Mohammed Abdullahi
    Goni, Baba Waru
    Mairari, Fatime Garba
    NIGERIAN JOURNAL OF BASIC AND CLINICAL SCIENCES, 2024, 21 (03) : 201 - 206
  • [8] Should HIV therapy be started at a CD4 cell count above 350 cells/μl in asymptomatic HIV-1-infected patients?
    Sabin, Caroline A.
    Phillips, Andrew N.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2009, 22 (02) : 191 - 197
  • [9] Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy
    Majekodunmi, Adedeji O.
    Thorne, Claire
    Malyuta, Ruslan
    Volokha, Alla
    Callard, Robin E.
    Klein, Nigel J.
    Lewis, Joanna
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (05) : E123 - E129
  • [10] The Effect of Intermittent IL-2 Therapy on CD4 T Cells in the Gut in HIV-1-Infected Patients
    Read, Sarah W.
    Ciccone, Emily J.
    Mannon, Peter J.
    Yao, Michael D.
    Chairez, Cheryl L.
    Davey, Richard T.
    Kovacs, Joseph A.
    Sereti, Irini
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 56 (04) : 340 - 343